Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Targeted therapy for HCC using dumbbell-like nanoparticles conjugated to monoclonal antibodies against VEGF and cancer stem cell receptors in mice

Fig. 3

Histopathological analysis of liver specimens of different groups after one month of treatment. A Pathological control group: showed marked disturbed liver architecture and marked polymorphism (H&E X10) B mAbs-conjugated nanoparticles-treated group: showed restoration of normal liver architecture, marked inflammatory infiltrate, mild polymorphism (H&E, 20X). C Avastin-treated group: showed moderate disturbed of liver architecture, moderate inflammatory infiltrate, mild increase mitosis, mild increase nuclear size and moderate polymorphism (H&E, 20X). D Nonconjugated nanoparticles-treated group: marked nodular and disturbed architecture, moderate inflammatory infiltrate, moderate increase mitosis, moderate increase nuclear size, bizarre shape of cells and marked polymorphism (H&E, 20X)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us